Vertex Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VERTEX PHARMS, and what generic alternatives to VERTEX PHARMS drugs are available?
VERTEX PHARMS has eight approved drugs.
There are forty-nine US patents protecting VERTEX PHARMS drugs.
There are seven hundred and seventy-nine patent family members on VERTEX PHARMS drugs in fifty-four countries and eighty-four supplementary protection certificates in nineteen countries.
Summary for Vertex Pharms
| International Patents: | 779 |
| US Patents: | 49 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 8 |
Drugs and US Patents for Vertex Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-002 | Mar 17, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-002 | Aug 7, 2018 | RX | Yes | Yes | 9,150,552 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Vertex Pharms | KALYDECO | ivacaftor | TABLET;ORAL | 203188-001 | Jan 31, 2012 | RX | Yes | Yes | 8,754,224 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-003 | Sep 2, 2022 | RX | Yes | No | 10,597,384 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-002 | Jun 8, 2021 | RX | Yes | No | 11,453,655 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Vertex Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vertex Pharms | INCIVEK | telaprevir | TABLET;ORAL | 201917-001 | May 23, 2011 | 8,529,882 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Premature patent expirations for VERTEX PHARMS
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| ⤷ Try a Trial | ⤷ Try a Trial |
International Patents for Vertex Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 6896619 | ⤷ Try a Trial |
| El Salvador | 2003000617 | ⤷ Try a Trial |
| Lithuania | 3150198 | ⤷ Try a Trial |
| China | 103254177 | ⤷ Try a Trial |
| Russian Federation | 2592368 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Vertex Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1320540 | C01320540/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: VERTEX PHARMACEUTICALS INCORPORATED, US |
| 2826776 | LUC00207 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/18/1306 20181106 |
| 1773816 | CR 2015 00038 | Denmark | ⤷ Try a Trial | PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLIN-3-CARBOXAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/12/782/001-002 20120725 |
| 2404919 | SPC/GB16/026 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: LUMACAFTOR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR AN ESTER PRODRUG THEREOF; REGISTERED: UK EU/1/15/1059/001 20151124; UK EU/1/15/1059/002 20151124 |
| 1773816 | 122015000050 | Germany | ⤷ Try a Trial | PRODUCT NAME: N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-CHINOLIN-3-CARBONSAEUREAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120723 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
